News
MXCT
1.470
-6.96%
-0.110
MaxCyte management to meet with Craig-Hallum
TipRanks · 5d ago
Weekly Report: what happened at MXCT last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at MXCT last week (1117-1121)?
Weekly Report · 11/24 09:17
Weekly Report: what happened at MXCT last week (1110-1114)?
Weekly Report · 11/17 09:17
MaxCyte reports Q3 results
Seeking Alpha · 11/13 10:48
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance
Seeking Alpha · 11/13 00:12
MaxCyte CFO Douglas Swirsky to Leave Post in 2026
Dow Jones · 11/12 23:36
*MaxCyte CFO Douglas Swirsky to Transition From Role in 1H of 2026
Dow Jones · 11/12 23:10
MaxCyte CFO Douglas Swirsky to transition out of role
TipRanks · 11/12 22:20
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
TipRanks · 11/12 22:05
MaxCyte CFO to step down in first half of 2026
Seeking Alpha · 11/12 21:34
MaxCyte Announces Q3 Results and Operational Restructuring
TipRanks · 11/12 21:33
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Reuters · 11/12 21:26
*MaxCyte: 2025 Core Rev Is Expected Flat to 10% Decline Compared to 2024, Inclusive of Rev From SeQure Dx >MXCT
Dow Jones · 11/12 21:25
MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026
Benzinga · 11/12 21:17
MaxCyte CFO Douglas Swirsky to Step Down in 2026
Reuters · 11/12 21:10
BRIEF-MaxCyte Announces Planned CFO Transition In 2026
Reuters · 11/12 21:08
Press Release: MaxCyte Announces Planned CFO Transition in 2026
Dow Jones · 11/12 21:08
Press Release: MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Dow Jones · 11/12 21:05
Insights into MaxCyte's Upcoming Earnings
Benzinga · 11/11 18:04
More
Webull provides a variety of real-time MXCT stock news. You can receive the latest news about Maxcyte through multiple platforms. This information may help you make smarter investment decisions.
About MXCT
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.